Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 23, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
MCBK: 20.30 (+1.04), ISIS: 59.49 (+1.88), ALNY: 93.52 (+0.97), GILD: 91.29 (+1.84), ASPS: 33.81 (+4.37), ACHN: 13.06 (+1.22), OFLX: 34.45 (unch), RCPT: 122.05 (+4.05), HGSH: 4.60 (-0.06), REXX: 5.17 (-0.17)
Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST
NICK: 14.80 (+0.20), JRJC: 5.81 (-0.11), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), VNDA: 14.69 (+1.11), EPAX: 2.46 (-0.08), FES: 1.19 (-0.01), NQ: 4.32 (-0.36), TECU: 3.59 (-0.14), VRML: 1.81 (+0.15), MYOS: 7.10 (+0.07), PME: 2.00 (+0.10), ESPR: 35.97 (-0.08), ALNY: 93.52 (+0.97), IDSA: 4.52 (-0.18), PRLS: 6.85 (+0.01), ACHN: 13.06 (+1.22), SKYS: 11.05 (-0.95), RCPT: 122.05 (+4.05), AGIO: 109.67 (+2.45)
Alnylam Pharmaceuticals Continues To Post Encouraging Results
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 11:15AM CST
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), ALXN: 181.96 (+3.09), SNY: 46.35 (+0.50)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D.
Business Wire - Fri Dec 19, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that Laurence Reid, Ph.D., the company's Chief Business Officer, plans to resign from the company, effective December 31, 2014. Dr. Reid will be joining Third Rock Ventures (TRV) as an Entrepreneur-in-Residence, and is expected to become a Chief Executive Officer for a TRV portfolio company in the future. Alnylam will initiate an external search to identify a new Chief Business Officer.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), MRK: 57.46 (+0.25)
Alnylam Elects Michael W. Bonney to Its Board of Directors
Business Wire - Thu Dec 18, 7:01AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the election of Michael W. Bonney to its Board of Directors. Mr. Bonney has served as Chief Executive Officer of Cubist Pharmaceuticals and as a member of its Board of Directors since June 2003. His experience prior to that includes leadership positions in successful biotech and pharmaceutical companies including Biogen Idec and Zeneca Pharmaceuticals (now AstraZeneca).
BIIB: 340.89 (+5.13), ALNY: 93.52 (+0.97)
Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 4:50PM CST
Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic disease and hepatic infectious disease.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50)
Additions/deletions from Nasdaq's Q-50 Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:54AM CST
GLNG: 36.67 (+1.15), MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), NUAN: 14.37 (-0.09), UTHR: 130.22 (+2.40), FSLR: 43.67 (-0.39), QQQ: 104.30 (+0.09), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), MPEL: 24.81 (+0.20), EXPE: 89.01 (+0.09), FFIV: 135.11 (+1.17), SSYS: 81.12 (+0.24), CAR: 64.23 (-0.25), JD: 24.61 (-0.12), SPLK: 61.49 (-0.11), MELI: 127.84 (+1.30), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08)
Quarterly Changes to the NXTQ Index
GlobeNewswire - Mon Dec 15, 6:20AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, December 22, 2014.
MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), EA: 48.06 (+0.23), UTHR: 130.22 (+2.40), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), SSYS: 81.12 (+0.24), FFIV: 135.11 (+1.17), MPEL: 24.81 (+0.20), AAL: 51.43 (+1.22), CAR: 64.23 (-0.25), NWS: 14.92 (-0.07), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08), GLNG: 36.67 (+1.15), NUAN: 14.37 (-0.09), FSLR: 43.67 (-0.39), LRCX: 81.13 (-0.44), EXPE: 89.01 (+0.09), SPLK: 61.49 (-0.11), JD: 24.61 (-0.12), MELI: 127.84 (+1.30), NDAQ: 48.74 (-0.40)
Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)
Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs"
Business Wire - Fri Dec 12, 6:00AM CST
--Cardio-Metabolic Disease, and Hepatic Infectious Disease STArs -
ALNY: 93.52 (+0.97)
Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis
Business Wire - Thu Dec 11, 3:00PM CST
--- First Patient Dosed in ENDEAVOUR will Trigger $25 Million Milestone to Alnylam from Genzyme, a Sanofi Company -
ALNY: 93.52 (+0.97)
Alnylam earns milestone on start of Phase 1 hypercholesterolemia trial
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:06AM CST
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21)
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Thu Dec 11, 7:01AM CST
--- Companies Expect to Present Initial Clinical Results in Mid-2015 -
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21)
Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 4:20PM CST
Alnylam (ALNY) announced positive early-stage data on ALN-AT3 of up to 57% antithrombin knockdown in initial multi-dose cohorts of hemophilia subjects.
BIIB: 340.89 (+5.13), ALNY: 93.52 (+0.97), ANIP: 55.24 (+1.79), AMGN: 160.67 (+3.15)
Alnylam therapeutic demonstrates effective AT knockdown in hemophilia cohort
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:30AM CST
ALNY: 93.52 (+0.97)
Critical Alerts For MannKind, Merck, Alnylam Pharmaceuticals, Nu Skin Enterprises and Organovo Released By InvestorsObserver
PR Newswire - Tue Dec 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MNKD, MRK, ALNY, NUS and ONVO.
ALNY: 93.52 (+0.97), ONVO: 6.84 (+0.03), NUS: 45.27 (+0.78), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)
Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 6:19AM CST
Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?
ALNY: 93.52 (+0.97)
Alnylam Reports Positive Initial Results for ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders, from Ongoing Phase 1 Trial
Business Wire - Mon Dec 08, 8:15PM CST
--- Subcutaneous Dose Administration of ALN-AT3 Found to be Well Tolerated in Healthy Volunteers and Initial Cohorts of Hemophilia Subjects -
ALNY: 93.52 (+0.97)
Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases
Business Wire - Sun Dec 07, 9:10AM CST
--- New Pre-Clinical Data Presented at American Society of Hematology (ASH) Meeting, Including Results Showing Robust C5 Knockdown of up to 99.2% and Inhibition of Serum Hemolytic Activity of up to 96.2% in Non-Human Primates for over Seven Months -
ALNY: 93.52 (+0.97)